Found: 5
Select item for more details and to access through your institution.
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01069-9
- By:
- Publication type:
- Article
Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study.
- Published in:
- Cancers, 2020, v. 12, n. 8, p. 2044, doi. 10.3390/cancers12082044
- By:
- Publication type:
- Article
Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study.
- Published in:
- Cancers, 2020, v. 12, n. 4, p. 773, doi. 10.3390/cancers12040773
- By:
- Publication type:
- Article
Dismal outcome of refractory or relapsing patients with myelodysplasia‐related acute myeloid leukemia partially alleviated by intensive chemotherapy.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 3, p. 1, doi. 10.1002/cam4.7003
- By:
- Publication type:
- Article
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes.
- Published in:
- 2021
- By:
- Publication type:
- Letter